OPKO Health (OPK) Q2 2024 earnings summary

Executive summary

• Entered a $250 million note purchase agreement with Healthcare Royalty, secured by Pfizer/NGENLA profit share, providing financial flexibility and retaining up to $100 million in potential milestone payments from Pfizer.

• Authorized a $100 million share repurchase program, representing about 10% of shares outstanding at current prices.

• Sale of select BioReference Health assets for $237.5 million expected to close by end of Q3, streamlining operations and focusing on core diagnostics.

• Net loss for Q2 2024 was $10.3 million ($0.01/share), improved from $19.6 million loss in Q2 2023.

• Progressing R&D for ModeX, including a first-in-class tetra-specific antibody (MDX-2001) and an Epstein-Barr vaccine candidate with Merck.

Financial highlights

• Q2 2024 total revenue: $182.2 million, down 31% year-over-year, mainly due to a one-time $90 million milestone in 2023.

• Diagnostic segment revenue increased 2% to $129.4 million in Q2 2024, driven by oncology growth.

• Pharmaceutical segment revenue was $40.5 million, down from $43.5 million in Q2 2023; Rayaldee sales were $7.2 million.

• Non-cash unrealized gain on GeneDx investment of $60.5 million in Q2 2024.

• Operating loss for Q2 2024 was $61.7 million, compared to operating income of $7.0 million in Q2 2023.

Outlook and guidance

• Anticipates closing the $237.5 million BioReference asset sale in Q3 2024, expected to strengthen liquidity.

• Pfizer gross profit share expected at $7–$9 million in Q3 and $15–$20 million for H2 2024.

• R&D expenses for Q3 2024 projected at $24–$28 million, reflecting increased ModeX activity.

• Annualized cost savings of $25 million expected by end of 2024 from cost reduction programs.

• Management believes current cash, proceeds from the 2044 Notes, and expected asset sale are sufficient for operations and debt service beyond 12 months.